Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Nucleophosmin (NPM1) is among the most frequently mutated genes in acute myeloid leukemia (AML). It is not known, however, how the resulting oncoprotein mutant NPM1 is leukemogenic. To reveal the cellular machinery in which NPM1 participates in myeloid cells, we analyzed the endogenous NPM1 protein interactome by mass spectrometry and discovered abundant amounts of the master transcription factor driver of monocyte lineage differentiation PU.1 (also known as SPI1). Mutant NPM1, which aberrantly accumulates in cytoplasm, dislocated PU.1 into cytoplasm with it. CEBPA and RUNX1, the master transcription factors that collaborate with PU.1 to activate granulomonocytic lineage fates, remained nuclear; but without PU.1, their coregulator interactions were toggled from coactivators to corepressors, repressing instead of activating more than 500 granulocyte and monocyte terminal differentiation genes. An inhibitor of nuclear export, selinexor, by locking mutant NPM1/PU.1 in the nucleus, activated terminal monocytic fates. Direct depletion of the corepressor DNA methyltransferase 1 (DNMT1) from the CEBPA/RUNX1 protein interactome using the clinical drug decitabine activated terminal granulocytic fates. Together, these noncytotoxic treatments extended survival by more than 160 days versus vehicle in a patient-derived xenotransplant model of NPM1/FLT3-mutated AML. In sum, mutant NPM1 represses monocyte and granulocyte terminal differentiation by disrupting PU.1/CEBPA/RUNX1 collaboration, a transforming action that can be reversed by pharmacodynamically directed dosing of clinical small molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892 · cited 2×
“Separation of cells into fractions was essential, since mutant NPM1 aberrantly accumulates in cytoplasm (1, 7).”
Self-citationOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443 · cited 7×
“…since Pu.1-helmed differentiation advances suppress Hox genes; (ii) origin of NPM1 mutations in lineage-commit-ted progenitors and not HSCs (9–11), since Pu.1 elimination from HSCs is antiproliferative/anticompetitive (42), while its knock-down from lineage-committed myeloid progenitors is…”
InfluentialTargeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130 · cited 1×
“PU.1 cooperates with CEBPA and RUNX1 to command granulomonocytic lineage fates (20–27) — Pu.1 -KO mice have reduced granulocytes and no monocytes (28, 29); Cebpa -KO mice have no granulocytes (30); definitive hematopoiesis is abrogated in Runx1 -KO mice (31); and ectopic expression of transcription…”
Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis
Novershtern, N., Subramanian, A., Lawton, L. N., Mak, R. H., Haining, W. N., McConkey, M. E., Habib, N., Yosef, N., Chang, C. Y., Shay, T., et al. (2011) · Cell · doi:10.1016/j.cell.2011.01.004 · Cited by 942
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“1-KO mice have reduced granulocytes and no monocytes (28, 29); Cebpa-KO mice have no granulocytes (30); definitive hematopoiesis is abrogated in Runx1-KO mice (31); and ectopic expression of transcription factor ensembles containing PU.”
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia
Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., Quake, S. R., & Majeti, R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004315 · Cited by 721
Corces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324297111 · Cited by 705
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
Iwasaki, H., Somoza, C., Shigematsu, H., Duprez, E. A., Iwasaki-Arai, J., Mizuno, S.-I., Arinobu, Y., Geary, K., Zhang, P., Dayaram, T., et al. (2005) · Blood · doi:10.1182/blood-2005-03-0860 · Cited by 433 · cited 4×
“…intermediate, inherently replicative stage of their advance along lineage differentiation axes seems to hinge on partial but not com-Figure genic (42–47); and (iii) mutual exclusivity of NPM1 with RUNX1 or biallelic CEBPA mutations (37–39), since some function of this master transcription factor…”
InfluentialZhang, D.-E., Hetherington, C. J., Meyers, S., Rhoades, K. L., Larson, C. J., Chen, H.-M., Hiebert, S. W., & Tenen, D. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1231 · Cited by 396
Dahl, R., Walsh, J. C., Lancki, D., Laslo, P., Iyer, S. R., Singh, H., & Simon, M. C. (2003) · Nature Immunology · doi:10.1038/ni973 · Cited by 380
PU.1 and C/EBPα/β convert fibroblasts into macrophage-like cells
Feng, R., Desbordes, S. C., Xie, H., Tillo, E. S., Pixley, F., Stanley, E. R., & Graf, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711961105 · Cited by 348
Arnold, I., & Watt, F. M. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00154-3 · Cited by 341
Smith, L., Hohaus, S., Gonzalez, D., Dziennis, S., & Tenen, D. (1996) · Blood · doi:10.1182/blood.v88.4.1234.bloodjournal8841234 · Cited by 332
Reprogramming Committed Murine Blood Cells to Induced Hematopoietic Stem Cells with Defined Factors
Riddell, J., Gazit, R., Garrison, B. S., Guo, G., Saadatpour, A., Mandal, P. K., Ebina, W., Volchkov, P., Yuan, G.-C., Orkin, S. H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.04.006 · Cited by 323 · cited 5×
“MYC target genes identified by others using ChIP-Seq (98), validated by separate analyses (Supplemental Figure 4).”
InfluentialHematopoietic stem cell function and survival depend on c-Myc and N-Myc activity
Laurenti, E., Varnum-Finney, B., Wilson, A., Ferrero, I., Blanco-Bose, W. E., Ehninger, A., Knoepfler, P. S., Cheng, P.-F., MacDonald, H. R., Eisenman, R. N., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.09.005 · Cited by 305
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295 · cited 1×
“Immunodeficient (NSG) mice were xenotransplanted with NPM1 / FLT3 -mutated primary AML cells (a subset of NPM1 -mutated AMLs with poor prognoses) (55).”
Hohaus, S., Petrovick, M. S., Voso, M. T., Sun, Z., Zhang, D.-E., & Tenen, D. G. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5830 · Cited by 284
Walsh, J. C., DeKoter, R. P., Lee, H.-J., Smith, E. D., Lancki, D. W., Gurish, M. F., Friend, D. S., Stevens, R. L., Anastasi, J., & Singh, H. (2002) · Immunity · doi:10.1016/s1074-7613(02)00452-1 · Cited by 262 · cited 2×
“1-ER (53), activating terminal monocytic fates (Supplemental Figure 7) and suppressing Hox gene expression.”
Multiple Functional Domains of AML1: PU.1 and C/EBPα Synergize with Different Regions of AML1
Petrovick, M. S., Hiebert, S. W., Friedman, A. D., Hetherington, C. J., Tenen, D. G., & Zhang, D.-E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3915 · Cited by 218 · cited 1×
“CEBPA and RUNX1 are expected to activate granulocytic fates (25, 27); however, the granulocyte differentiation program, like the monocyte differentiation program, is suppressed in AML versus normal granulocytes (Supplemental Figure 11 and Supplemental Table 5).”
Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis
Arends, C. M., Galan-Sousa, J., Hoyer, K., Chan, W., Jäger, M., Yoshida, K., Seemann, R., Noerenberg, D., Waldhueter, N., Fleischer-Notter, H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0047-7 · Cited by 194
Will, B., Vogler, T. O., Narayanagari, S., Bartholdy, B., Todorova, T. I., da Silva Ferreira, M., Chen, J., Yu, Y., Mayer, J., Barreyro, L., et al. (2015) · Nature Medicine · doi:10.1038/nm.3936 · Cited by 127 · cited 3×
“Sim-Figure kills AML cells, even as partial loss of function of any one of these is leukemogenic (17, 43, 68–72); and accordingly, NPM1 , RUNX1 , and biallelic CEBPA mutations, though highly recurrent in AML, are mutually exclusive (37–39).”
Negrotto, S., Ng, K. P., Jankowska, A. M., Bodo, J., Gopalan, B., Guinta, K., Mulloy, J. C., Hsi, E., Maciejewski, J., & Saunthararajah, Y. (2012) · Leukemia · doi:10.1038/leu.2011.207 · Cited by 90
Self-citationSaunthararajah, Y. (2013) · Hematology · doi:10.1182/asheducation-2013.1.511 · Cited by 79
Self-citationNygren, J. M., Bryder, D., & Jacobsen, S. E. W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.201 · Cited by 72
Ng, K. P., Ebrahem, Q., Negrotto, S., Mahfouz, R. Z., Link, K. A., Hu, Z., Gu, X., Advani, A., Kalaycio, M., Sobecks, R., et al. (2011) · Leukemia · doi:10.1038/leu.2011.159 · Cited by 68 · cited 3×
“…in AML cells versus granulocytes/monocytes, but loss of function in AML cells is evidenced by suppression of hundreds of monocyte and granulocyte terminal differentiation genes versus monocytes/granulocytes, even as commitment and proliferation programs are similarly activated (21, 65–67).”
Self-citationRUNX1 regulates corepressor interactions of PU.1
Hu, Z., Gu, X., Baraoidan, K., Ibanez, V., Sharma, A., Kadkol, S., Munker, R., Ackerman, S., Nucifora, G., & Saunthararajah, Y. (2011) · Blood · doi:10.1182/blood-2010-10-312512 · Cited by 63 · cited 6×
“…DNMT1 depletion by decitabine (or its pro-drug 5-azacytidine) in patients with myeloid malignancies containing sundry mutations and translocations (20, 21, 65–67 , Together, our results indicating that mutant NPM1 dislocates PU.1 into cytoplasm could guide pharmacodynamically directed dosing of…”
InfluentialSelf-citationPU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway
Zhou, J., Wu, J., Li, B., Liu, D., Yu, J., Yan, X., Zheng, S., Wang, J., Zhang, L., Zhang, L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.384 · Cited by 53
Houston, I. B., Kamath, M. B., Schweitzer, B. L., Chlon, T. M., & DeKoter, R. P. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.04.005 · Cited by 49 · cited 3×
“PU.1 is essential for monocyte differentiation, contributes to granulocyte differentiation (23, 42–47), and is considered a master transcription factor, commanding other transcription factors and hundreds of genes to dictate cell fates (32).”
Gu, X., Hu, Z., Ebrahem, Q., Crabb, J. S., Mahfouz, R. Z., Radivoyevitch, T., Crabb, J. W., & Saunthararajah, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562447 · Cited by 42 · cited 4×
“…in AML cells versus granulocytes/monocytes, but loss of function in AML cells is evidenced by suppression of hundreds of monocyte and granulocyte terminal differentiation genes versus monocytes/granulocytes, even as commitment and proliferation programs are similarly activated (21, 65–67).”
InfluentialSelf-citation
Cited by
NPM1-mutated acute myeloid leukemia: from bench to bedside
Falini, B., Brunetti, L., Sportoletti, P., & Martelli, M. P. (2020) · Blood · doi:10.1182/blood.2019004226 · Cited by 337
Self-citationThe nuclear export protein XPO1 — from biology to targeted therapy
Azmi, A. S., Uddin, M. H., & Mohammad, R. M. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00442-4 · Cited by 279
Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
McKenzie, M. D., Ghisi, M., Oxley, E. P., Ngo, S., Cimmino, L., Esnault, C., Liu, R., Salmon, J. M., Bell, C. C., Ahmed, N., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.001 · Cited by 91
Higa, K. C., Goodspeed, A., Chavez, J. S., De Dominici, M., Danis, E., Zaberezhnyy, V., Rabe, J. L., Tenen, D. G., Pietras, E. M., & DeGregori, J. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200560 · Cited by 57
Taylor, S. J., Stauber, J., Bohorquez, O., Tatsumi, G., Kumari, R., Chakraborty, J., Bartholdy, B. A., Schwenger, E., Sundaravel, S., Farahat, A. A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01911-7 · Cited by 22
Metadata
- Authors
- Gu, X., Ebrahem, Q., Mahfouz, R. Z., Hasipek, M., Enane, F., Radivoyevitch, T., Rapin, N., Przychodzen, B., Hu, Z., Balusu, R., Cotta, C. V., Wald, D., Argueta, C., Landesman, Y., Martelli, M. P., Falini, B., Carraway, H., Porse, B. T., Maciejewski, J., Jha, B. K., & Saunthararajah, Y.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-07-17
- Volume
- 128
- Issue
- 10
- Pages
- 4260-4279
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2883977121
- Cited by
- 115
- References
- 32
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.